Replies to post #285576 on NorthWest Biotherapeutics Inc (NWBO)

[Sir Pumpernickel]

I guess you missed this part:
The ongoing phase 3 clinical trial has two cohorts where all patients undergo surgery and radiation. Afterwards, patients are given either DCVax-L alongside other standard of care drugs (SOC) or a placebo alongside SOC. Out of the 331 patients enrolled in the two cohorts, 233 deaths are required to determine whether DCVax-L possess an overall survival benefit, in addition to another endpoint measuring progression free survival, which was reached in 2017.